Source link : https://newshealth.biz/health-news/imlunestrant-benefit-holds-after-cdk4-6-therapy-progression/
Combination therapy with imlunestrant and the CDK4/6 inhibitor abemaciclib led to a significant progression-free survival (PFS) benefit compared with imlunestrant alone in women with estrogen receptor (ER)–positive and human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who had experienced disease progression following CDK4/6 inhibitor therapy, according to a subgroup analysis from the EMBER-3 […]
The post Imlunestrant Benefit Holds After CDK4/6 Therapy Progression first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-16 05:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8